Entering text into the input field will update the search result below

J&J's long-acting injectable two-drug regimen successful in late-stage HIV study

Aug. 15, 2018 7:52 AM ETJohnson & Johnson (JNJ) StockBy: Douglas W. House, SA News Editor4 Comments
  • Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical announces positive topline results from a Phase 3 clinical trial, ATLAS, evaluating a once-per-month injectable two-drug regimen for the maintenance treatment of HIV-1 infection.
  • The study demonstrated the non-inferiority of Janssen's long-acting rilpivirine plus ViiV Healthcare's cabotegravir compared to a daily oral three-drug regimen at week 48.
  • Complete results will be submitted for presentation at a future medical conference.

Recommended For You

About JNJ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
JNJ--
Johnson & Johnson